You are here

Article Text

Article menu
Download PDFPDF
Original Articles
ATP7B antisense oligodeoxynucleotides increase the cisplatin sensitivity of human ovarian cancer cell line SKOV3ipl
  1. W. Xu,
  2. B. Cai,
  3. J. L. Chen,
  4. L. X. Li,
  5. J. R. Zhang,
  6. Y. Y. Sun and
  7. X. P. Wan
  1. Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai, People's Republic of China
  1. Address correspondence and reprint requests to: Xiaoping Wan, MD, PhD, Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated First People's Hospital, No. 85 Wujin Road, Shanghai 200080, People's Republic of China. Email: wanxiaoping61{at}126.com

Abstract

The objective of this study was to investigate the effect of ATP7B antisense oligodeoxynucleotides (ASODNs) on regulating the sensitivity to cisplatin in ovarian carcinoma cell line SKOV3ip1. The ATP7B ASODNs and the corresponding sense oligodeoxynucleotide (SODN) as control were transfected into SKOV3ip1 cells by lipofectamine-2000. The changes of ATP7B were detected by reverse transcription–polymerase chain reaction, flow cytometry, and Western blotting. The survival rate of the SKOV3ip1 cells was assessed by MTT assay. Compared with nontransfected cell, the transfer of ASODN/lipofectin (LF) into SKOV3ip1 cells resulted in (1) 73.70% and 48.30% reduction of ATP7B in messenger RNA and protein, respectively, (2) an obviously decreased intracellular fluorescence intensity from 79.42 to 50.87 (P< 0.01), and (3) a decreased IC50 value for cisplatin from 126.63 to 80.90 μ mol/L (P< 0.01), while no significant changes were detected for groups treated with SODN/LF and LF only. ASODN transfection can inhibit the expression of ATP7B and increase the cisplatin sensitivity in SKOV3ip1 cells.

  • antisense oligodeoxynucleotide
  • ATP7B
  • cisplatin
  • SKOV3ip1

https://doi.org/10.1136/ijgc-00009577-200807000-00016

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.